C-MET Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in C-MET Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ C-MET Non-Small Cell Lung Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the C-MET Non-Small Cell Lung Cancer Pipeline Report

* June 2024:- AbbVie- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
* May 2024: Apollomics Inc.- Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
* DelveInsight's C-MET Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for C-MET Non-Small Cell Lung Cancer treatment.
* The leading C-MET Non-Small Cell Lung Cancer Companies such as Novartis, Apollomics Inc., Abbvie, Janssen Research and Development , and others.
* Promising C-MET Non-Small Cell Lung Cancer Therapies such as Glumetinib, Telisotuzumab vedotin, Tepotinib, APL-101 Oral Capsules, MCLA-129, Osimertinib, PLB1001 , and others.

Stay informed about the cutting-edge advancements in C-MET Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ C-MET Non-Small Cell Lung Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

C-MET Non-Small Cell Lung Cancer Emerging Drugs Profile

* EGF-816 (Nazartinib): Novartis Oncology

Novarti's lead drug candidate, EGF-816 (Nazartinib), is small molecule in combination with INC280 is in development for the treatment of non-small cell lung cancer. Clinical trials data demonstrated that EGF-816 (Nazartinib) for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) has beneficial effects. The drug is a new molecule which is an epidermal growth factor receptor antagonist that blocks the function of protein EGFR.

* APL 101 (Bozitinib): Appolomics Inc.

Apollomics drug APL 101 (Bozitinib) is an orally administered small molecule currently being evaluated for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and has demonstrated good safety and efficacy profile in phase II trials. APL 101 (Bozitinib) is an anti-neoplastics which inhibits the C-met protein.

Learn more about C-MET Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking C-MET Non-Small Cell Lung Cancer Research and development projects @ C-MET Non-Small Cell Lung Cancer Unmet Needs [https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Subcutaneous
* Intravenous
* Oral
* Intramuscular
* Molecule Type

C-MET Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Small molecules
* Natural metabolites
* Monoclonal antibodies
* Product Type

Discover the latest advancements in C-MET Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ C-MET Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the C-MET Non-Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* C-MET Non-Small Cell Lung Cancer Companies- Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others.
* C-MET Non-Small Cell Lung Cancer Therapies- Glumetinib, Telisotuzumab vedotin, Tepotinib, APL-101 Oral Capsules, MCLA-129, Osimertinib, PLB1001, and others.
* C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of C-MET Non-Small Cell Lung Cancer Pipeline on our website @ C-MET Non-Small Cell Lung Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Collaboration Deals
* Late Stage Products (Phase III)
* EGF 816 (Nazartinib): Novartis
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* APL 101 (Bozitinib): Apollomics Inc.
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Products
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Unmet Needs
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Market Drivers and Barriers
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Future Perspectives and Conclusion
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Analyst Views
* C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cmet-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.